 | Up a level |
Haber, Philipp K; Castet, Florian; Torres-Martin, Miguel; Andreu-Oller, Carmen; Puigvehí, Marc; Maeda, Miho; Radu, Pompilia; Dufour, Jean-Francois; Verslype, Chris; Czauderna, Carolin; Marquardt, Jens U; Galle, Peter R; Vogel, Arndt; Bathon, Melanie; Meyer, Tim; Labgaa, Ismail; Digklia, Antonia; Roberts, Lewis R; Mohamed Ali, Mohamed A; Mínguez, Beatriz; ... (2023). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology, 164(1), 72-88.e18. Elsevier 10.1053/j.gastro.2022.09.005
Akbil, Bengisu; Meyer, Tim; Stubbemann, Paula; Thibeault, Charlotte; Staudacher, Olga; Niemeyer, Daniela; Jansen, Jenny; Mühlemann, Barbara; Doehn, Jan; Tabeling, Christoph; Nusshag, Christian; Hirzel, Cédric; Sanchez, David Sökler; Nieters, Alexandra; Lother, Achim; Duerschmied, Daniel; Schallner, Nils; Lieberum, Jan Nikolaus; August, Dietrich; Rieg, Siegbert; ... (2022). Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of clinical immunology, 42(6), pp. 1111-1129. Springer 10.1007/s10875-022-01252-2
Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Nault, Jean-Charles; Sapisochin, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Hołówko, Wacław; El Kassas, Mohamed; Mocan, Tudor; Bouattour, Mohamed; Merle, Philippe; Hoogwater, Frederik J H; Alqahtani, Saleh A; Reeves, Helen L; Pinato, David J; Giorgakis, Emmanouil; Meyer, Tim; ... (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP reports, 3(3), p. 100260. Elsevier 10.1016/j.jhepr.2021.100260
Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555
